Annovis Bio (ANVS) Soars 19.12% on Phase 3 Trial Progress

Annovis Bio (ANVS) surged 19.12% today, marking its second consecutive day of gains, with a total increase of 22.73% over the past two days. The share price reached its highest level since February 2025, with an intraday gain of 26.47%.

Over the past five years, the strategy of buying ANVS shares after they reached a high and holding for one week resulted in significant underperformance. The strategy yielded a return of -87.27%, with a Sharpe ratio of -0.50, indicating poor risk-adjusted returns. The maximum drawdown of -93.54% and a CAGR of -57.98% further highlight the strategy's substantial losses and declining value over time. In contrast, the benchmark returned 49.45% during the same period, demonstrating the futility of this strategy in comparison to a passive approach.

Annovis Bio's stock has shown a strong upward trend over the past two weeks, driven by several key developments. The company's pivotal Phase 3 trial of buntanetap for early Alzheimer's disease has garnered significant attention, contributing to a notable rise in its share price. This trial is a critical milestone for Annovis Bio, as it aims to demonstrate the efficacy of its treatment in a large-scale clinical setting.

In addition to its clinical progress, Annovis Bio has made strategic appointments to enhance its capabilities. The company recently appointed Hui Liu as Director of Biostatistics, a move aimed at strengthening its clinical trial operations. This appointment is part of a broader strategy to ensure the success of its ongoing pivotal trials and to position the company for future growth.

Analysts have also expressed optimism about Annovis Bio's prospects, giving the company a consensus rating of "Strong Buy" with a 2025 price prediction of $28.38. This positive outlook is supported by the company's technical indicators, which include buy signals from both short and long-term moving averages, as well as the Moving Average Convergence Divergence (MACD).

Despite these positive indicators, there is a divergence due to falling volume on higher prices, which may suggest caution for potential changes in the near future. However, the overall sentiment remains bullish, with investors and analysts alike recognizing the potential of Annovis Bio's innovative treatments and strategic developments.